the rationale for bemcentinib plus pembrolizumab in axl-positive nsclc
Published 4 years ago • 283 plays • Length 0:43Download video MP4
Download video MP3
Similar videos
-
2:35
a phase ii study of bemcentinib with pembrolizumab in patients with advanced nsclc
-
1:16
rationale for evaluating ceritinib in alk-positive patients with nsclc
-
6:10
axl inhibitor bemcentinib in combination with chemotherapy exerts anti-leukaemic activity in aml...
-
3:04
management of frontline alk nsclc: brigatinib vs. alectinib
-
4:57
keynote-024 shows prolonged nsclc survival benefit with pembrolizumab | julie brahmer
-
2:02
case 4: upfront osimertinib in metastatic egfr nsclc
-
1:47
quality of life results from pembrolizumab vs chemotherapy in gastric or gastroesophageal juncti...
-
1:18
ceritinib for lung cancer treatment
-
2:31
axitinib plus pembrolizumab in advanced rcc
-
2:51
pirtobrutinib shows efficacy in btki refractory waldenström’s macroglobulinemia patients
-
2:54
pembrolizumab or egfr tyrosine kinase inhibitors in nsclc?
-
1:34
second-line treatments in alk-rearranged nsclc
-
2:02
therapeutic options available to patients with r/r waldenström’s macroglobulinemia
-
6:32
asco 2019 lung cancer round table - new cancer research: long term outcomes of pembrolizumab
-
0:59
dr. johung on prognosis of patients with alk-rearranged nsclc and brain metastases
-
3:02
osimertinib for treating non-small cell lung cancer
-
2:53
oleclumab plus osimertinib for advanced egfrm nsclc
-
1:35
afatinib for advanced egfrm-positive nsclc